CEA-Scan gets approvable letter from FDA
It's been a long road back for monoclonal antibody developer Immunomedicsand its CEA-Scan imaging agent, but the end is finally in sight.The Morris Plains, NJ, company reported this month that the Foodand Drug Administration has issued an approvable
It's been a long road back for monoclonal antibody developer Immunomedicsand its CEA-Scan imaging agent, but the end is finally in sight.The Morris Plains, NJ, company reported this month that the Foodand Drug Administration has issued an approvable letter for theagent.
CEA-Scan's path through the FDA's regulatory maze was entangledin 1994 when the agency issued a non-approvable letter for thecolorectal cancer imaging agent. Immunomedics worked with theagency to bring CEA-Scan's product license application (PLA) intoa form that FDA reviewers could accept, and an FDA panel recommendedapproval of the product in February (SCAN 2/28/96).
Final marketing approval for CEA-Scan is now subject mainlyto product labeling, Immunomedics said. Immunomedics has assignedU.S. marketing rights for the agent to Mallinckrodt Medical (SCAN4/10/96).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
